Primary central nervous system lymphoma in a patient treated with natalizumab

Andreas Schweikert, Marcus Kremer, Florian Ringel, Thomas Liebig, Justus Duyster, Olaf Stüve, Bernhard Hemmer, Achim Berthele

Research output: Contribution to journalArticle

59 Scopus citations

Abstract

A 40-year-old man with relapsing-remitting multiple sclerosis (MS) developed primary central nervous system lymphoma (PCNSL) after having received 21 doses of natalizumab monotherapy. PCNSL is a disease of the elderly, with the majority of patients being diagnosed in the 7th to 8th decade of life. Immunodeficiency, iatrogenic immunosuppression, and some autoimmune diseases are known as predisposing conditions, and in these patients PCNSL peaks in the 4th decade. Because there is no increased prevalence of PCNSL in MS, and the patient was otherwise not immunocompromised, an association between natalizumab therapy and PCNSL cannot be ruled out.

Original languageEnglish (US)
Pages (from-to)403-406
Number of pages4
JournalAnnals of Neurology
Volume66
Issue number3
DOIs
StatePublished - Oct 22 2009

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Primary central nervous system lymphoma in a patient treated with natalizumab'. Together they form a unique fingerprint.

  • Cite this

    Schweikert, A., Kremer, M., Ringel, F., Liebig, T., Duyster, J., Stüve, O., Hemmer, B., & Berthele, A. (2009). Primary central nervous system lymphoma in a patient treated with natalizumab. Annals of Neurology, 66(3), 403-406. https://doi.org/10.1002/ana.21782